 Morpholinos are in development as pharmaceutical therapeutics targeted against pathogenic organisms such as bacteria or viruses and for amelioration of genetic diseases . These synthetic oligos were conceived by James E. Summerton ( Gene Tools ) and originally developed in collaboration with Dwight D. Weller at a biotech corporation ( formerly Antivirals , renamed AVI <unk> , renamed Sarepta Therapeutics ) . The experimental Morpholino drug <unk> from Sarepta Therapeutics is currently ( April 2016 ) in Phase III clinical trials for treatment of some mutations causing Duchenne muscular dystrophy . 
